John W. Kasckow
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
John W. Kasckow has a total of 112 co-authors. Here are the top co-authors by number of shared publications:
Ajit Regmi
4 shared publications- Dewleen G. Baker
University of California San Diego, Department of Psychiatry, La Jolla, CA, USA
3 shared publications James J. Mulchahey
Phase 2 Discovery, Inc., 3130 Highland Avenue, Cincinnati, OH, USA
3 shared publicationsSomaia Mohamed
3 shared publications- Thomas D. Geracioti
Research Service, VA Medical Center, 3200 Vine St, Box 151, Cincinnati, OH 45220, USA
3 shared publications Brendan Carroll
2 shared publications
Latest Publications
- 1 January 2011
- Published by Taylor & Francis in Psychotherapy Research
- Vol. 21 (1) , 41-53
Narrative evolution and assimilation of problematic experiences in a case of pharmacotherapy for schizophrenia
This case study applied the assimilation model to examine the changing narrative of an outpatient with schizophrenia and symptoms of depression across a successful pharmacotherapy. The assimilation model describes how clients assimilate painful, problematic experiences. Therapeutic progress is understood to reflect increasing assimilation, measured by the Assimilation of Problematic Experiences Scale (APES). The authors used a 15-min semistructured interview (Problematic Experiences Questionnaire) to elicit narrative descriptions of the patient's problems and coping across five interviews throughout his 12-week treatment. They describe how the patient's narrative and APES ratings of his main problems by two clinicians changed in concert through treatment, explain these developments using assimilation concepts, and interpret the results in relation to assimilation and insight in schizophrenia.
- 1 January 2011
- Published by Taylor & Francis in Psychotherapy Research
- Vol. 21 (1) , 41-53
Narrative evolution and assimilation of problematic experiences in a case of pharmacotherapy for schizophrenia
This case study applied the assimilation model to examine the changing narrative of an outpatient with schizophrenia and symptoms of depression across a successful pharmacotherapy. The assimilation model describes how clients assimilate painful, problematic experiences. Therapeutic progress is understood to reflect increasing assimilation, measured by the Assimilation of Problematic Experiences Scale (APES). The authors used a 15-min semistructured interview (Problematic Experiences Questionnaire) to elicit narrative descriptions of the patient's problems and coping across five interviews throughout his 12-week treatment. They describe how the patient's narrative and APES ratings of his main problems by two clinicians changed in concert through treatment, explain these developments using assimilation concepts, and interpret the results in relation to assimilation and insight in schizophrenia.
- 1 August 2008
- Published by Elsevier in The American Journal of Geriatric Psychiatry
- Vol. 16 (8) , 660-663
Functioning in Middle Aged and Older Patients With Schizophrenia and Depressive Symptoms: Relationship to Psychopathology
- 1 August 2008
- Published by Elsevier in The American Journal of Geriatric Psychiatry
- Vol. 16 (8) , 660-663
Functioning in Middle Aged and Older Patients With Schizophrenia and Depressive Symptoms: Relationship to Psychopathology
- 8 March 2007
- Published by Cambridge University Press (CUP)
- p. 59-77
Late-Life Schizophrenia
The Spectrum of Psychotic Disorders - edited by Daryl Fujii March 2007
- 8 March 2007
- Published by Cambridge University Press (CUP)
- p. 59-77
Late-Life Schizophrenia
The Spectrum of Psychotic Disorders - edited by Daryl Fujii March 2007
- 2 February 2006
- Published by Elsevier in Brain Research
- Vol. 1073-1074, 325-331
Aging associated changes in amygdalar corticotropin-releasing hormone (CRH) and CRH-binding protein in Fischer 344 rats
- 2 February 2006
- Published by Elsevier in Brain Research
- Vol. 1073-1074, 325-331
Aging associated changes in amygdalar corticotropin-releasing hormone (CRH) and CRH-binding protein in Fischer 344 rats
- 1 July 2004
- Published by Elsevier in Journal of the American Medical Directors Association
- Vol. 5 (4) , 242-248
The Use of Novel Antipsychotics in the Older Patient With Neurodegenerative Disorders in the Long-Term Care Setting
- 1 July 2004
- Published by Elsevier in Journal of the American Medical Directors Association
- Vol. 5 (4) , 242-248
The Use of Novel Antipsychotics in the Older Patient With Neurodegenerative Disorders in the Long-Term Care Setting
- 1 March 2004
- Published by Elsevier in Progress in Neuro-Psychopharmacology and Biological Psychiatry
- Vol. 28 (2) , 291-295
Effects of the vanilloid agonist olvanil and antagonist capsazepine on rat behaviors
- 1 March 2004
- Published by Elsevier in Progress in Neuro-Psychopharmacology and Biological Psychiatry
- Vol. 28 (2) , 291-295
Effects of the vanilloid agonist olvanil and antagonist capsazepine on rat behaviors
- Retracted
- 17 May 2003
- Published by Elsevier in Life Sciences
- Vol. 73 (6) , 769-781
RETRACTED: In vitro regulation of corticotropin-releasing hormone
- 17 May 2003
- Published by Elsevier in Life Sciences
- Vol. 73 (6) , 769-781
RetractedRETRACTED: In vitro regulation of corticotropin-releasing hormone
- 9 April 2003
- Published by Wiley in Journal of Neuroendocrinology
- Vol. 15 (5) , 521-529
Corticotropin‐Releasing Hormone (CRH) Expression and Protein Kinase A Mediated CRH Receptor Signalling in an Immortalized Hypothalamic Cell Line
Corticotropin‐releasing hormone (CRH) is a 41 amino acid neuropeptide which plays an important role in the stress response in the hypothalamus. We describe the development of an immortalized hypothalamic cell line which expresses CRH. We hypothesized that this cell line would possess the relevant characteristics of parvocellular CRH‐expressing neurones such as glucocorticoid receptor (GR) expression and vasopressin (VP) coexpression. For production of hypothalamic cells, embryonic day 19 rat pup hypothalami were dissected and dissociated into tissue culture dishes. They were immortalized by retrovirus‐mediated transfer of the SV40 large T antigen gene at 3 days of culture and then screened for expression of CRH following dilution cloning. One cell line was chosen (IVB) which exhibited CRH‐like immunoreactivity (CRH‐LI) and expressed CRH, VP and CRH1 receptor RNA via the reverse transcriptase‐polymerase chain reaction. In addition, the cell line expressed the neuronal marker, microtubule‐associated protein‐2. We verified that the CRH‐LI from IVB cell lysates coeluted with CRH standard via reversed‐phase high‐performance liquid chromatography (HPLC). Furthermore, oxidation of the lysate converted its HPLC profile to that identical with oxidized CRH standard. In addition, IVB cells exhibited high affinity binding to CRH. Incubation of IVB cells with CRH lead to increases in cAMP levels and protein kinase A activity in a concentration‐dependent manner. Incubation of IVB cells with CRH also resulted in increases in phospho‐cyclic‐AMP response element binding protein (CREB) imunostaining as detected by immunocytochemical analysis. Finally, CRH treatment of IVB cell lines has been linked to CREB‐mediated gene expression as determined via the PathDetect CREB trans‐reporting system. The characteristics of IVB cells, such as CRH and VP coexpression, GR expression and a biologically active CRH‐R1‐mediated signalling pathway, suggest that this neuronal cell line may serve as model of parvocellular CRH neurones.
- 9 April 2003
- Published by Wiley in Journal of Neuroendocrinology
- Vol. 15 (5) , 521-529
Corticotropin‐Releasing Hormone (CRH) Expression and Protein Kinase A Mediated CRH Receptor Signalling in an Immortalized Hypothalamic Cell Line
Corticotropin‐releasing hormone (CRH) is a 41 amino acid neuropeptide which plays an important role in the stress response in the hypothalamus. We describe the development of an immortalized hypothalamic cell line which expresses CRH. We hypothesized that this cell line would possess the relevant characteristics of parvocellular CRH‐expressing neurones such as glucocorticoid receptor (GR) expression and vasopressin (VP) coexpression. For production of hypothalamic cells, embryonic day 19 rat pup hypothalami were dissected and dissociated into tissue culture dishes. They were immortalized by retrovirus‐mediated transfer of the SV40 large T antigen gene at 3 days of culture and then screened for expression of CRH following dilution cloning. One cell line was chosen (IVB) which exhibited CRH‐like immunoreactivity (CRH‐LI) and expressed CRH, VP and CRH1 receptor RNA via the reverse transcriptase‐polymerase chain reaction. In addition, the cell line expressed the neuronal marker, microtubule‐associated protein‐2. We verified that the CRH‐LI from IVB cell lysates coeluted with CRH standard via reversed‐phase high‐performance liquid chromatography (HPLC). Furthermore, oxidation of the lysate converted its HPLC profile to that identical with oxidized CRH standard. In addition, IVB cells exhibited high affinity binding to CRH. Incubation of IVB cells with CRH lead to increases in cAMP levels and protein kinase A activity in a concentration‐dependent manner. Incubation of IVB cells with CRH also resulted in increases in phospho‐cyclic‐AMP response element binding protein (CREB) imunostaining as detected by immunocytochemical analysis. Finally, CRH treatment of IVB cell lines has been linked to CREB‐mediated gene expression as determined via the PathDetect CREB trans‐reporting system. The characteristics of IVB cells, such as CRH and VP coexpression, GR expression and a biologically active CRH‐R1‐mediated signalling pathway, suggest that this neuronal cell line may serve as model of parvocellular CRH neurones.
- 23 November 2002
- Published by Wiley in Journal of Neurochemistry
- Vol. 64 (5) , 2358-2361
Exposure to an Antisense Oligonucleotide Decreases Corticotropin-Releasing Factor Receptor Binding in Rat Pituitary Cultures
Corticotropin-releasing factor (CRF) appears to integrate the endocrine, autonomic, immunologic, and behavioral responses of mammals to stress. To investigate further the role of CRF in the CNS, we have begun investigating the usefulness of "antisense knockdown" strategies directed against the CRF receptor using rat anterior pituitary gland primary cell cultures. The 15-mer antisense (5' CTG-CGG-GCG-CCG-TCC 3') and "scrambled" control (5' CGT-CCG-CGC-GCT-GCG 3') oligonucleotides were synthesized based on the rat CRF receptor sequence just downstream of the initiation codon. In each of four separate experiments, exposure to 10 mumol/L of antisense oligonucleotide for 40-67 h resulted in significant (17-36%) decreases in 125I-ovine CRF binding to pituitary cells as compared with either control (no oligonucleotide) or 10 mumol/L of "scrambled" oligonucleotide. Moreover, compared with scrambled oligonucleotide, exposure to 10 mumol/L of antisense oligonucleotide, which produced a 22% decrease in CRF receptor binding, also resulted in a significant attenuation of the adrenocorticotrophic hormone response following a 30-min challenge with 100 pmol/L of CRF. Thus, CRF receptor antisense oligonucleotides apparently reduce functional expression of CRF receptors. This technique may be useful in studying the kinetics of CRF receptor production and the physiological functions of CRF receptors within the CNS.
- 23 November 2002
- Published by Wiley in Journal of Neurochemistry
- Vol. 64 (5) , 2358-2361
Exposure to an Antisense Oligonucleotide Decreases Corticotropin-Releasing Factor Receptor Binding in Rat Pituitary Cultures
Corticotropin-releasing factor (CRF) appears to integrate the endocrine, autonomic, immunologic, and behavioral responses of mammals to stress. To investigate further the role of CRF in the CNS, we have begun investigating the usefulness of "antisense knockdown" strategies directed against the CRF receptor using rat anterior pituitary gland primary cell cultures. The 15-mer antisense (5' CTG-CGG-GCG-CCG-TCC 3') and "scrambled" control (5' CGT-CCG-CGC-GCT-GCG 3') oligonucleotides were synthesized based on the rat CRF receptor sequence just downstream of the initiation codon. In each of four separate experiments, exposure to 10 mumol/L of antisense oligonucleotide for 40-67 h resulted in significant (17-36%) decreases in 125I-ovine CRF binding to pituitary cells as compared with either control (no oligonucleotide) or 10 mumol/L of "scrambled" oligonucleotide. Moreover, compared with scrambled oligonucleotide, exposure to 10 mumol/L of antisense oligonucleotide, which produced a 22% decrease in CRF receptor binding, also resulted in a significant attenuation of the adrenocorticotrophic hormone response following a 30-min challenge with 100 pmol/L of CRF. Thus, CRF receptor antisense oligonucleotides apparently reduce functional expression of CRF receptors. This technique may be useful in studying the kinetics of CRF receptor production and the physiological functions of CRF receptors within the CNS.
- 1 June 2002
- Published by Elsevier in The American Journal of Geriatric Psychiatry
- Vol. 10 (3) , 344-347
Citalopram Treatment of Minor Depression in Elderly Men: An Open Pilot Study
- 1 June 2002
- Published by Elsevier in The American Journal of Geriatric Psychiatry
- Vol. 10 (3) , 344-347
Citalopram Treatment of Minor Depression in Elderly Men: An Open Pilot Study